Akèy › Kansè nan tete › Wisconsin
Etid klinik pou Kansè nan tete nan Wisconsin
44 etid pou Kansè nan tete ap chèche patisipan nan sit nan Wisconsin.
Vil nan Wisconsin
- Milwaukee23 etid
- Madison22 etid
- Green Bay7 etid
- Sheboygan6 etid
- La Crosse6 etid
- Stevens Point5 etid
- Wausau5 etid
- Eau Claire5 etid
- Oshkosh5 etid
- Manitowoc4 etid
- Racine4 etid
- Neenah4 etid
- Kenosha4 etid
- Watertown4 etid
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Wisconsin Carbone Cancer Center, Madison
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Regional Medical Center - Appleton, Appleton
- ak 50 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UW Health Carbone Cancer Center, Madison
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- University of Wisconsin, Madison
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07102381Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Wisconsin Institute for Medical Research, Madison
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06625775A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07060807A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- University of Wisconsin-Madison ( Site 0024), Madison
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312176Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Milwaukee
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- University of Wisconsin, Madison
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- ThedaCare Physicians - Appleton North, Appleton
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- University of Wisconsin - Carbone Cancer Center, Madison
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Froedtert & MCW Cancer Center, Milwaukee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Mayo Clinic Health System - Eau Claire, Eau Claire
- Mayo Clinic Health System - La Crosse, La Crosse
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07405801Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07287917Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Gunderson Health, La Crosse
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- University of Wisconsin, Madison
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT04886531The Vanguard Study: Testing a New Way to Screen for Cancer
- Zablocki Veterans Administration Medical Center, Milwaukee
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- Duluth Clinic Ashland, Ashland
- ak 59 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Sheboygan Cancer & Blood Specialists, Sheboygan
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612Study of 18F-FFNP Breast PET/MRI
- UW Carbone Cancer Center, Madison
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Aug 31, 2026 · NCT06086704Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06582017Biomarkers to Detect Endocrine Therapy Resistance
- UW Carbone Cancer Center, Madison
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06067503Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
- Froedtert Hospital, Milwaukee
Ap rekrite
Laj 65 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07227077Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06106477E-Mindfulness Approaches for Living After Breast Cancer
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Cancer Care - Berlin, Berlin
- ak 21 plis
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222Integrated Cancer Repository for Cancer Research
- Bellin Memorial Hospital, Green Bay
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
- University of Wisconsin Carbone Cancer Center, Madison
Ap rekriteFaz 2
Laj 40 ak plis · Fanm · Mizajou Jun 11, 2026 · NCT03936478De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Langlade Hospital and Cancer Center, Antigo
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- ak 43 plis
Ap rekriteFaz 3
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Aspirus Langlade Hospital, Antigo
- ThedaCare Regional Cancer Center, Appleton
- Ascension Saint Elizabeth Hospital, Appleton
- ak 61 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Medical College of Wisconsin, Milwaukee
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT04075305Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT02926690Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- University of Wisconsin, Madison
Ap rekriteFaz 4
Laj 18 a 64 · Tout sèks · Mizajou Jan 22, 2026 · NCT04373564EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Aurora Cancer Care - Wauwatosa, Wauwatosa
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT06401421SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Milwaukee
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Oct 14, 2025 · NCT06361940Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.